Akeso Announced the Inclusion in China’s National Reimbursement Drug List Of Cadonilimab and Ivonescimab
2024-11-28
Akeso Announced the Inclusion in China’s National Reimbursement Drug List Of Cadonilimab and Ivonescimab
Akeso's Penpulimab Combination Therapy for First-line Treatment of Hepatocellular Carcinoma Accepted by NMPA  
2024-11-22
Akeso's Penpulimab Combination Therapy for First-line Treatment of Hepatocellular Carcinoma Accepted by NMPA  
Akeso Biopharma to Attend Jefferies London Healthcare Conference and Morgan Stanley 23rd Asia Pacific Summit
2024-11-18
Akeso Biopharma to Attend Jefferies London Healthcare Conference and Morgan Stanley 23rd Asia Pacific Summit
Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting
2024-11-08
Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab
2024-11-01
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab
2024-10-31
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab
Akeso Released Complete Phase 3 Data for Gumokimab (AK111, IL-17) in Moderate to Severe Plaque Psoriasis
2024-10-28
Akeso Released Complete Phase 3 Data for Gumokimab (AK111, IL-17) in Moderate to Severe Plaque Psoriasis
IGCS Late Breaking Abstract and The Lancet: Akeso Published Positive PFS and OS Results from Phase 3 First-Line Study of Cadonilimab in Cervical Cancer
2024-10-16
IGCS Late Breaking Abstract and The Lancet: Akeso Published Positive PFS and OS Results from Phase 3 First-Line Study of Cadonilimab in Cervical Cancer
Akeso Secures $250 Million USD to Propel Global Expansion of Its Innovative Drug Pipeline
2024-10-13
Akeso Secures $250 Million USD to Propel Global Expansion of Its Innovative Drug Pipeline
Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population
2024-09-30
Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population
Akeso’s Ebronucimab（PCSK9) Approved for Two Indications for the Treatment of Hypercholesterolemia in China
2024-09-30
Akeso’s Ebronucimab（PCSK9) Approved for Two Indications for the Treatment of Hypercholesterolemia in China
ESMO 2024 | Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivonescimab with or without CD47 Antibody plus FOLFOXIRI for mCRC
2024-09-18
ESMO 2024 | Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivonescimab with or without CD47 Antibody plus FOLFOXIRI for mCRC
开心体育app | 开云新人注册88元 | 竞技宝体育首页 | fb体育官方 | milan米兰官网入口 | mk足球 | 赢博网页 | 澳洲体彩幸运10官网（中国）幸运有限公司 | 悟空官方网站 |